
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Over 10 years ago that question was the basis for one of my editorialsin Dermatology Times. In the ensuing years the incidence of skin cancerhas continued explosive expansion! Not only is melanoma now expanding tooccur in greater than 1:75 babies born in 2000, but it is also the mostrapidly increasing cancer in the United States.